Neurocrine Biosciences, Inc. (NASDAQ: NBIX) has announced the appointment of Dr. Sanjay Keswani, M.D., as the Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani brings over 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas. He has previously held executive leadership roles at both large pharmaceutical companies and small biotechnology firms, and has been instrumental in the development of several first-in-class and best-in-class approved medicines.
Before joining Neurocrine, Dr. Keswani served as the President and Chief Executive Officer of Immunobrain, a clinical-stage biotechnology firm focused on developing therapeutics for patients with neurodegenerative diseases. He also previously held the position of Senior Vice President and R&D Head for Neuroscience, Ophthalmology, and Rare Diseases at Hoffman La Roche, as well as Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb.
Dr. Keswani's appointment comes as a transition from Dr. Eiry W. Roberts, M.D., who has served as CMO for the past seven years and will remain with Neurocrine in a strategic advisory role. During Dr. Roberts' tenure, she led indication expansion efforts for Ingrezza® (valbenazine) capsules and the Crinecerfont development program, which led to U.S. Food and Drug Administration approval of Crenessity™ (crinecerfont). She also oversaw the recent successful phase 2 proof of concept studies for Osavampator and NBI-1117568, both of which are moving into registrational programs this year.
Neurocrine Biosciences is a leading neuroscience-focused biopharmaceutical company with a portfolio that includes FDA-approved treatments for various conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company also has a robust pipeline, with multiple compounds in mid* to late-phase clinical development across its core therapeutic areas.
The appointment of Dr. Keswani signifies an exciting and pivotal time for Neurocrine as the company continues its commitment to developing much-needed treatments for patients using a rigorous scientific approach involving diverse modalities, including small molecule, peptide, antibody, and gene therapy. The market has reacted to these announcements by moving the company's shares -7.2% to a price of $95.44. For more information, read the company's full 8-K submission here.
